BioInvent to receive $25M up front in exchange for rights to select 3 targets which were identified by BioInvent’s F.I.R.S.T platform & n-CoDeR library & is eligible to receive option exercise fee, success-based milestones along with royalties
BioInvent will lead the future development, commercialization & other activities for the development candidate. Exelixis will be granted the option to in-license target programs upon the identification of a development candidate directed toward that target
The collaboration will broaden Exelixis’ portfolio of Ab-based therapies & combine BioInvent’s expertise with Exelixis’ expertise & resources in Ab engineering & ADC technologies to develop & commercialize cancer therapies
Ref: Bussinesswire | Image: Exelixis
